Location History:
- Adliswil, CH (2011 - 2016)
- Gattikon, CH (2017)
Company Filing History:
5 out of 36 
2 out of 5 
1 out of 5 Years Active: 2011-2017
Title: Peter Lichtlen: Innovator in Antibody Development
Introduction
Peter Lichtlen is a prominent inventor based in Adliswil, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for medical applications. With a total of nine patents to his name, Lichtlen's work focuses on innovative solutions for treating various disorders.
Latest Patents
Lichtlen's latest patents include groundbreaking inventions such as stable and soluble antibodies inhibiting TNFα. This invention relates to scFv antibodies and Fab fragments that are specifically designed for stability, solubility, and low immunogenicity. These antibodies are intended for the diagnosis and treatment of TNFα-related disorders. Another notable patent involves nucleic acids encoding antibodies that bind to the extracellular domain of the receptor tyrosine kinase ALK. This antibody is particularly useful for the local treatment of tumors, including glioblastoma.
Career Highlights
Throughout his career, Lichtlen has worked with several notable companies, including Esbatech, Alcon Biomedical Research Unit, and Delenex Therapeutics AG. His experience in these organizations has allowed him to advance his research and contribute to the development of innovative therapeutic solutions.
Collaborations
Lichtlen has collaborated with esteemed colleagues such as Alcide Barberis and Adrian Auf Der Maur. These partnerships have further enriched his research and development efforts in the field of biotechnology.
Conclusion
Peter Lichtlen's contributions to antibody development have positioned him as a key figure in the biotechnology industry. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.